Day RS - Search Results

1

Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.

Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. Getzenberg RH, et al. Among authors: day rs. Urology. 1997 Dec;50(6):999-1006. doi: 10.1016/S0090-4295(97)00408-1. Urology. 1997. PMID: 9426741

2

Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4.

Konety BR, Nguyen TS, Dhir R, Day RS, Becich MJ, Stadler WM, Getzenberg RH. Konety BR, et al. Among authors: day rs. Clin Cancer Res. 2000 Jul;6(7):2618-25. Clin Cancer Res. 2000. PMID: 10914702

3

A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis.

Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson RR, Hofacker J, Branch RA. Trump DL, et al. Cancer Chemother Pharmacol. 1997;39(4):349-56. doi: 10.1007/s002800050582. Cancer Chemother Pharmacol. 1997. PMID: 9025776 Clinical Trial.

4

Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer.

Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Osborn JL, et al. Urol Oncol. 1995 Sep-Oct;1(5):195-8. doi: 10.1016/1078-1439(95)00061-5. Urol Oncol. 1995. PMID: 21224117 Free article.

5

Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate.

Matin K, Egorin MJ, Ballesteros MF, Smith DC, Lembersky B, Day RS, Johnson CS, Trump DL. Matin K, et al. Among authors: day rs. Cancer Chemother Pharmacol. 2002 Sep;50(3):179-85. doi: 10.1007/s00280-002-0484-9. Epub 2002 Jul 19. Cancer Chemother Pharmacol. 2002. PMID: 12203099 Clinical Trial.

6

Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase.

Smith DC, Gerson SL, Liu L, Donnelly S, Day R, Trump DL, Kirkwood JM. Smith DC, et al. Clin Cancer Res. 1996 Jul;2(7):1129-34. Clin Cancer Res. 1996. PMID: 9816278 Clinical Trial.

7

All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes.

Adedoyin A, Stiff DD, Smith DC, Romkes M, Bahnson RC, Day R, Hofacker J, Branch RA, Trump DL. Adedoyin A, et al. Cancer Chemother Pharmacol. 1998;41(2):133-9. doi: 10.1007/s002800050719. Cancer Chemother Pharmacol. 1998. PMID: 9443626 Clinical Trial.

8

Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant.

Jain AB, Todo S, Fung JJ, Venkataramanan R, Day R, Bryant J, Abu-Elmagd KM, Alessiani M, Takaya S, Tzakis A, et al. Jain AB, et al. Transplant Proc. 1991 Dec;23(6):3023-5. Transplant Proc. 1991. PMID: 1721347 Free PMC article. Clinical Trial. No abstract available.

9

Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.

Kirkwood JM, Mascari RA, Edington HD, Rabkin MS, Day RS, Whiteside TL, Vlock DR, Shipe-Spotloe JM. Kirkwood JM, et al. Among authors: day rs. Cancer. 2000 Jun 15;88(12):2693-702. Cancer. 2000. PMID: 10870051 Clinical Trial.

10

Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer.

Ramalingam S, Belani CP, Day R, Zamboni BA, Jacobs SA, Jett JR. Ramalingam S, et al. Ann Oncol. 2004 Feb;15(2):247-51. doi: 10.1093/annonc/mdh061. Ann Oncol. 2004. PMID: 14760117 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

226 results

Search Page

Filters